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Summary.-Reported elevations of total serum sialic acid may be a result of shed
tumour-related membrane sialylglycoprotein and/or concurrent elevation of non-
specific, acute-phase reactant sialylglycoprotein. To clarify further the specificity
and sensitivity of serum sialic acid monitoring, analyses of sialic acid by the thio-
barbituric acid method and acute-phase reactants by radial immunodiffusion were
made using the same malignant melanoma patients' sera. Preliminary studies of
IgG, IgA, IgM, ceruloplasmin and C-reactive protein suggested that these would not
be valuable monitors of tumour burden. Single serum samples from 59 melanoma
patients and age- and sex-matched controls were further examined for sialic acid,
a -acid glycoprotein, a -antitrypsin, haptoglobin, and a2-macroglobulin. Patients
were grouped according to tumour burden. In pairwise statistical tests, differences
between groups tended to be greater for sialic acid than for acute-phase reactants.
On discriminant analysis, sialic acid was clearly the most significant single discrimi-
nator between groups, with an F statistic ofP<0-00005.Althougha,-acid glycoprotein
was quite strongly correlated with sialic acid, it was not such a good discriminator
and did not add significantly to the predictive power of sialic acid alone.
ACUTE-PHASE REACTANTS (APR) can
serve as effective monitors of tumour
burden. Features of special interest are
the relative ease of measurement and free-
dom from the restrictions of histological
specificity ofmostimmunodiagnostic tests.
Broad clinical applicability is suggested
by the variety of neoplasms where APR
concentration is related to tumour burden,
including leukaemia (Child et al., 1977)
gliomas (Weiss etal., 1979) and carcinomas
of breast (Coombes et al., 1977) bowel
(Ward et al., 1977b), lung (Hollinshead
et al., 1977) ovary (Mueller et al., 1971)
cervix (te Velde et al., 1979) and prostate
(Ward et al., 1977a). In each case serum
concentration of APR has been directly
related to tumour burden.
We have been examining the role of
tumour-related sialylglycoproteins as rela-
tively nonspecific tumour markers. In-
creased membrane density of sialic acid
(N-acetyl neuraminic acid) and associated
elevation of sialyltransferase activity has
been reported in a variety of malignant
and transformed cells (Mabry & Carubelli,
1972; Van Beek et al., 1973). We and
others have found significant in vitro
tumour cell production of sialylglyco-
proteins and relatively rapid appearance
in tissue-culture media (Bhavanandan
etal., 1977; Grim etal., 1976). This suggests
that elevated serum sialylglycoproteins or
relatedsialyltransferase activitymightbea
common feature in cancer patients. We
have shown that there is a strong correla-
tion between serum sialic acid and tumour
burden in malignant melanoma, and that
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this relatively simple measurement ap-
pears to be a better correlate than related
sialyltransferase activity (Silver et al.,
1 979a).
In addition to the sialic acid and sialyl-
transferase of tumour-cell origin there is a
nonspecific component. Both serum sialic
acid and sialyltransferase activity can act
as nonspecific acute-phase reactants (Silver
et al., 1 979a). In the case ofsialic acid this
can be explained by the demonstrated
sialic acid content, of some acute-phase
reactant (APR) glycoproteins (Koj, 1974).
Since APRs have already been suggested
as valuable monitors of tumour burden, it
would be of interest to investigate the
relationship of total serum sialic acid and
APR in cancer patients. The purpose of
this study was to evaluate both serum
sialic acid and known APR sialylglyco-
proteins as monitors of tumour burden in
malignant melanoma. The APRs selected
for study included the following: al-acid
glycoprotein (AGP), al-antitrypsin (AAT),
haptoglobin (HPT), cA2-macroglobulin
(AMCG), ceruloplasmin (CPL), and immuno-
globulins G, A, and M. C-reactive protein
(CRP) was also considered, although its
sialic acid content is not significant
(Fischer & Gill, 1975).
MATERIALS AND METHOD)S
Patientls. Sera from 59 melanoma patients
were used to study sialic acid, AGP, AAT,
HPT and AMG. In order to maintain con-
tinuity with earlier data, the population is
the same as used in a previous study (Silver
et al., 1979a). Pre-study evaluation and group-
ing according to objective assessment of
tumour burden was as described in detail by
Silver et al (1979a). Group I patients had no
evidence of disease at the time of serum
sampling. Group II patients had a relatively
small tumour burden consisting of either
primary melanoma, local recurrence, or in-
transit metastases estimated at less than 5 g.
Group III patients all had relativelv advanced
regional or distant metastatic disease. clearly
greater than a tumour burden of 5 g. Sex-
and age-matched normal control sera were
selected from our serum collection for
comparison with each patient group. Addi-
tional sera from 10 Group Ifl melanoma
patients wNere selected as a preliminary
evaluation of CPL, CRP, IgG, IgA, and TgM.
Serum. collectio;i. Whole blood w,as col-
lected in 10 ml glass vacutainer tubes and the
samples allowsed to clot at room temperature
for 1 h. After centrifugation at 500 g for 10
min., the sera wNere removed in 0-8ml aliquots,
placed in polypropylene tubes and stored at
-70°C until used. Before assay the serum
samples were allowed to thawr at room
temperature.
Serum assay. Determination of bound
sialic acid was by a modification of the thio-
barbituric acid technique (Warren. 1959) as
described by us (Silver et al., 1978, 1979a).
In addition to the usual inter-assay and
intra-assay controls, analysis included calcu-
lation of extinction coefficients for each
experiment from a series of standard sialic
acid and deoxvribose solutions. The calcula-
tion of extinction coefficients and sialic acid
concentration was aided by a compuiter
programme allowing for minor contamination
with interfering substances (Silver et al.,
1978).
APR proteins (AGP, AAT, HPT, AMG,
CPL, CRP, IgG, IgA and IgM) were quanti-
tate(l by radial immunodiffusion (Mancini et
al., 1965) using standardized reagents (Behr-
ing Diagnostics, Montreal, Canada).
RESULTS
The preliminary evaluation of immuno-
globulins, CPL and CRP is represented in
Table I. Neither the immunoglobulins nor
CPL were remarkably raised in the face of
extensive malignant melanoma. They were
not further investigated. However, 9/10
of the same patients' sera did show clear
CRP elevations. This was further studied
in sera selected from patients with known
tuimour burden, evaluated as described
above. Again CRP was elevated in associa-
tion with advanced disease, this time in
7/10 Group III patients. Ofthe other sera,
there were CRP elevations in 0/10 nor-
mals, 1/16 Group I patients, and 0/8 Group
II patients. Since CRP does not contain
significant sialic acid, and elevations were
not seen in any limited-disease (Group II)
patients, this APR was not further studied.
Wte further investigated those APRs
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TABLE I.-Fraction of sera in each group with possible tumour-marker elevations
Normal
Melanoma
Rheumatoid arthritis
IgG
0/8
0/10
3/9
IgA
0/8
2/10
4/9
I200
150
L
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FIGURE. Percent change from normal for
each tumour marker in Groups I, II and
III patients. Each vertical bar represents
1 s.d. from the mean, denoted by a horizon-
tal line. Abbreviations: S, sialic acid; G,
(x-acid glycoprotein; T, cal-antitrypsin; H,
haptoglobin; M, cX2-macroglobulin.
that could contribute significantly to total
serum sialic acid content, and might also
act as sensitive monitors of tumour bur-
den: AGP, AAT, HPT and AMG. These
APRsandsialic acidwere measuredin each
of the 59 melanoma sera from patients
with known tumour burden and age- and
sex-matched normal controls. The mean
serum values are shown in the Figure.
Patients with advanced disease (Group
III) had clear marker elevations, with the
exception ofAMG where no clear pattern is
seen. An increase in serum concentration
IgM
4/8
4/10
4/9
Ceruloplasmin
0/8
1/10
3/10
C-reactive protein
0/8
9/10
10/10
of some markers is suggested for Group II
patients over normal controls or Group I.
Pairwise statistical evaluation using the
Mann-Whitney test is shown in Table II.
As suggested by the Figure, AMG is
generally alessreliable indicator oftumour
burden than other APRs. The remaining
APRs and sialic acid showed significant
increases in concentration for Group III
patients. Similar comparisons between
other groups were less remarkable. For
most comparisons confidence limits (P
values) were less for sialic acid than for
the APRs. Since sialic acid was not
uniformly superior for all pairwise com-
parisons, it was felt desirable to test
whether sialic acid performed uniformly
better overall. In order to assess this, a
stepwise discriminant analysis was under-
taken in which consecutive entry of the
variables was controlled by computer
package (Kiecka, 1975). Two analyses
were performed. The first included data
from the 3 groups of melanoma
patients and normal controls; the second
examined the melanoma patients alone.
In the initial analysis the first variable
chosen was sialic acid. Not only was this
variable deemed to be the most significant
single predictor of discrimination between
the groups, but the discrimination was also
TABLE II. Statistical significance (P) ofserum group comparisonsfor eachtumour marker
(Mann-Whitney test)
Tumour marker
Groups
compared
N vs I
N vs II
N vs III
I vs II
I vs III
II Vs III
SA
0-4 (NS)
0-006
< 0 00003
0-02
< 0 00003
0-00006
AGP
0-2 (NS)
0-002
<000003
0 05
0 00005
0 004
AAT
0-2 (NS)
0 04
< 0 00003
0-01
< 0 00003
0 004
HPT
0-2 (NS)
0-5 (NS)
<000003
0-3 (NS)
0-0001
0-0002
AMG
0-00016
0-4 (NS)
0-2 (NS)
0-02
0 008
0-5 (NS)
Abbreviations: SA, sialic acid; AGP, cal-acid glycoprotein; AAT, oul-antitrypsin; HPT, haptoglobin;
AMG, O2-macroglobulin; N, normal.
NS, not significant.
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TABLE III.-Number ofsera in each patient group with tumour-marker elevations
Tumour marker
l I
SA
1 (3%)
4 (33%)
16 (94%)
AGP
1 (3%)
1 (8%)
11 (64%)
AAT
0
0
13 (76%)
HPT
1 (3%)
0
7 (41%)
AMG
0
2 (17%)
1 (6%)
Abbreviations: as in Table II.
extremely significant (F= 73 6 with 3 and
117 degrees offreedom, P< 0.00005). Very
similar results were obtained on the second
discriminant analysis, in which attention
was restricted to the 3 melanoma groups.
Sialic acid was again picked as the best
single discriminating variable (F= 63-7
with 2 and 59 degrees of freedom, P<
0 00005). Observations onthewithin-group
correlation matrix showed that sialic acid
measurements were quite strongly corre-
lated with AGP, but AGP was not such
agooddiscriminator assialic acid. Thiswas
reinforced elsewhere in the analysis, since
AGP was not picked by the program
as another variable in the discriminant
function.
Each marker was also examined to
determine how many melanoma sera were
outside the normal range established by
the normal control sera (Table III). This
type of analysis more closely mimics
clinical practice, where the significance of
a test is usually determined by comparison
with a normal range. The upper limit of
normal determined by us was similar to
that established by others (Koj, 1974;
Fischer & Gill, 1975). As detailed in
Table III, serum elevations were more
frequent for sialic acid than for any ofthe
APRs. The number of patients with
elevated sialic acid levels and/or any APR
elevation was not significantly greater
than those with sialic acid elevations
alone (Table IV).
DISCUSSION
There hasbeen anevolvingre-evaluation
ofthe clinical role oftumour markers. The
initial prospect of highly sensitive and
specific immunochemical assays used as
diagnostic screening aids was justifiably
met with great interest. Further experi-
ence has tempered this enthusiasm. This is
bestillustrated by accumulatedexperience
with the most thoroughly evaluated
immunodiagnostic tests, carcinoembryonic
antigen (CEA) and xyl-fetoprotein (AFP).
Most clinical laboratories have found that
CEA testing lacks the histological speci-
ficity or sensitivity for small tumour bur-
den necessary for diagnostic screening
(Dhar et al., 1972). While AFP is more
sensitive and specific, its use as a screening
test will probably be restricted to well
defined high-risk populations (People's
Republic of China, 1974; Silver et al.,
1973). On the other hand, tumour markers
appear well suited to provide important
non-diagnostic information on staging,
evaluation ofprognosis, detection of early
recurrence or quantitation of tumour
response to treatment (Parks et al., 1974;
TABLE IV.-Number of sera in each patient group with sialic acid and acute-phase
reactant elevations
Tumour marker combination
SA+AGP SA+AAT SA+HPT SA+AMG
2 (7%) 1 (3%) 2 (7%) 1 (3%)
4 (33%) 4 (33%) 4 (33%) 5 (42%)
17 (100%) 16 (94%) 16 (94%) 17 (100%)
Abbreviations: as in Table II.
Group
I
II
III
Total
patients
30
12
17
Group
I
II
III
Total
patients
30
12
17
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Herrera et al., 1977). Such information is
crucial in the rational application of the
proliferating complex treatment pro-
grammes available for an increasing num-
ber ofhuman neoplasms. Accurate staging
and prognosis are especially important in
the selection of appropriate high-risk
patients for aggressive surgery or poten-
tially toxic adjuvant therapy programmes.
Detection ofearly recurrence and objective
assessment of tumour burden in response
to treatment are essential for the prompt
selection of effective systemic therapy
among alternatives. For these examples of
post-diagnostic patient management, a
tumour marker need not be specific for a
given histological type. On the contrary,
a relatively nonspecific marker would have
a broad range of clinical applicability not
presently enjoyed by many "specific"
tumour antigens. Potential tumour mar-
kers in this category include selected
APRs (Ward et al., 1977a), and sialic acid
(Silver et al., 1978, 1979a).
Our preliminary investigation elimina-
ted CRP, CPL and the immunoglobulins
as unlikely correlates of tumour burden in
malignant melanoma patients. In more
detailed investigations, serum concentra-
tions of AGP, AAT, HPT and AMG, both
AGP and AAT correlated well with tumour
burden (Table II). However, increased
serum sialic acid was more frequently
seen than APR elevations (Table III) and
sialic acid results generally showed greater
statistical significance (Table II). This
was confirmed on discriminant analysis.
Sialic acid was picked as the best dis-
criminating variable, and the APRs did
not add to the discriminating power of
sialic acid alone.
The basis for the apparent superiority
of sialic acid as a tumour marker in this
study is yet to be determined. It may be
that total serum sialic acid is acting as a
correlate of combined total APR. There
was nothing in the statistical analysis
supporting this view. The observed results
are perhaps better explained by tumour
sialylglycoprotein production. Certainly,
increased sialic acid has been repeatedly
observed at the tumour-cell surface for a
variety of neoplasms, and sialylglyco-
proteins appear to be rapidly shed by these
cells (Bhavanandan et al., 1977; Grim
et al., 1976). We ourselves and others
have also developed further evidence that
the sialylglycoprotein of tumour origin
can be quantitated independently of
APR (Silver et al., 1979b; Lipton et al.,
1978). If total serum sialic acid is a
composite of both APR activity and
specific tumour-cell production, it might
be expected that sialic acid would reflect
tumour burden more closely than any of
the APRs.
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